30th week of 2021 patent applcation highlights part 26 |
Patent application number | Title | Published |
20210230251 | UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER - A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (i CAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the i CAR comprises an extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope absent from mammalian tumor cells due to loss of heterozygosity (LOH) but present at least on all cells of related mammalian normal tissue; and an intracellular domain comprising at least one signal transduction element that inhibits an effector immune cell is provided. Vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided. | 2021-07-29 |
20210230252 | TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF - In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders. | 2021-07-29 |
20210230253 | TRANSGENIC CHICKEN THAT MAKES ANTIBODIES WITH LONG CDR-H3S STABILIZED BY MULTIPLE DISULFIDE BRIDGES AND DIVERSIFIED BY GENE CONVERSION - This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene. | 2021-07-29 |
20210230254 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF - The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection. | 2021-07-29 |
20210230255 | ANTIBODY DIRECTED AGAINST A TAU-DERIVED NEUROTOXIC PEPTIDE AND USES THEREOF - The present invention refers to an antibody or an antigen binding fragment thereof against a tau-derived neurotoxic peptide for use in the treatment and/or prevention of Alzheimer's disease (AD) or a non-AD tauopathy, as well as pharmaceutical compositions comprising the same. | 2021-07-29 |
20210230256 | NOVEL TARGET FOR ANTI-CANCER AND IMMUNE-ENHANCING - The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351. | 2021-07-29 |
20210230257 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF - The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human transthyretin (TTR). The anti-TTR antibodies or antigen-binding fragments thereof are useful, for example, in detecting TTR and in treating TTR amyloidosis in a subject. | 2021-07-29 |
20210230258 | ANTIBODIES TO PfGARP KILL PLASMODIUM FALCIPARUM MALARIA PARASITES AND PROTECT AGAINST INFECTION AND SEVERE DISEASE - Provided herein are methods, compositions and kits for preventing and treating malaria. Also included herein are kits for preventing and treating malaria. | 2021-07-29 |
20210230259 | CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 2021-07-29 |
20210230260 | ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF - The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia. | 2021-07-29 |
20210230261 | BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES - The invention provides buffered aqueous formulations of bevacizumab. The invention further provides methods of making buffered formulations of bevacizumab. The invention provides methods of treating eye disorders, particularly wet age-related macular degeneration and macular edema by administering the buffered antibody compositions of the disclosure. | 2021-07-29 |
20210230262 | METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST - Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSF | 2021-07-29 |
20210230263 | Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses Thereof - An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases. | 2021-07-29 |
20210230264 | ANTI-HUMAN INTERLEUKIN 17A MONOCLONAL ANTIBODY AND APPLICATION THEREOF - Disclosed by the present invention are an anti-human interleukin 17A monoclonal antibody and an application thereof. The epitope of the monoclonal antibody binding to human interleukin 17A comprises 78th asparagine (N78). The antibody may be used to treat rheumatoid arthritis, psoriasis, multiple sclerosis, psoriatic arthritis, plaque psoriasis and/or ankylosing spondylitis. | 2021-07-29 |
20210230265 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST - Methods for treating or preventing COPD and associated conditions in a patient are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody or antigen-binding fragment thereof, are provided. | 2021-07-29 |
20210230266 | IL-11 ANTIBODIES - Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same. | 2021-07-29 |
20210230267 | Human IL-23 Antigen Binding Proteins - Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided. | 2021-07-29 |
20210230268 | INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA - A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient. | 2021-07-29 |
20210230269 | IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2 - The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (K | 2021-07-29 |
20210230270 | ANTI-THYROID HORMONE (T4) RECOMBINANT ANTIBODY OR ANTIGEN BINDING FRAGMENT - The present invention relates to the fields of antibodies, antigen binding fragments and immunodiagnostics. Specifically, the invention relates to a recombinant anti-body or antigen binding fragment for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Also, the present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes the recombinant antibody or antigen binding fragment of the present invention, as well as an ex-pression vector and host cell comprising the nucleic acid molecule of the present invention. Still, the present invention relates to a method of producing a recombi-nant antibody or antigen binding fragment for binding T4 thyroid hormone and hal-ogenated bisphenol A, a test kit and an immunoassay comprising the recombinant antibody or antigen binding fragment of the present invention, and a method for determining T4 thyroid hormone and/or halogenated bisphenol A levels in a sam-ple of a subject. Still further, the present invention relates to a method of treating a sample, e.g. an immunoaffinity-based sample preparation method for enrich-ment of the halogenated bisphenol A from a sample. | 2021-07-29 |
20210230271 | ANTI-CD37 ANTIBODIES - Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology. | 2021-07-29 |
20210230272 | ANTIBODY TARGETING CLDN18.2, BISPECIFIC ANTIBODY, ADC, AND CAR, AND APPLICATIONS THEREOF - Provided is an antibody targeting CLDN18.2. The antibody targeting CLDN18.2 comprises VL and/or VH; the VL comprises the following CDR sequences: a VL CDR amino acid sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; a VL CDR2 amino acid sequence as shown in SEQ ID NO: 13; and a VL CDR3 amino acid sequence as shown in SEQ ID NO: 14; and the VH comprises the following CDR sequences; a VH CDR1 amino acid sequence as shown in SEQ ID NO: 15; a VH CDR2 amino acid sequence as shown in SEQ ID NO: 16; and a VH CDR3 amino acid sequence as shown in SEQ ID NO: 17. Further disclosed are a bispecific antibody targeting CLDN18.2, a conjugates of the antibody, a CAR molecule targeting CLDN18.2 and a cell comprising same, and applications thereof. | 2021-07-29 |
20210230273 | HUMANIZED ANTI-CD200 ANTIBODIES AND USES THEREOF - Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200. Also provided are uses of these proteins in therapeutic applications, such as the treatment of cancer and in conjunction with organ transplantation. Also provided are nucleic acids encoding the heavy and/or light chain variable regions (or heavy and/or light chains) of the antibodies, vectors comprising the nucleic acids, and cells that produce the antibodies. | 2021-07-29 |
20210230274 | ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS - Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions. | 2021-07-29 |
20210230275 | T CELL REGULATION - Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies. | 2021-07-29 |
20210230276 | TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS - Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used. | 2021-07-29 |
20210230277 | ANTI-PD-L1/ANTI-CD47 BISPECIFIC ANTIBODY - Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409. | 2021-07-29 |
20210230278 | Antibodies binding to HLA-A2/MAGE-A4 - The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease. | 2021-07-29 |
20210230279 | NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY - New antibodies and methods of use are described. | 2021-07-29 |
20210230280 | MONOCLONAL ANTIBODY ANTI-FGFR4 - The present disclosure relates to monoclonal antibodies anti-FGFR4 and their use as medicaments and diagnostic agents. In particular, it relates to an antibody which specifically binds to the acid box domain of FGFR4 and to specific portions thereof. Nucleic acids coding for said antibody, vectors and host cells for their expression and production, antibody-drug conjugates and pharmaceutical compositions comprising said antibody are also within the scope of the present disclosure. The present disclosure also relates to antibodies anti-FGFR4 for use for detecting, killing, affecting or inhibiting development and/or differentiation of colon cancer stem cells. | 2021-07-29 |
20210230281 | DOSING OF A BISPECIFIC ANTIBODY THAT BIND CD123 AND CD3 - The methods described here are directed to treating human subjects with bispecific anti-CD 123×anti-CD3 antibodies. | 2021-07-29 |
20210230282 | PROPHYLACTIC AGENT, ONSET-SUPPRESSING AGENT OR THERAPEUTIC AGENT FOR PROGRESSIVE IMMUNE DEMYELINATING DISEASES - The present invention provides a prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases comprising, as an active ingredient, a substance capable of suppressing or inhibiting production of prolactin. | 2021-07-29 |
20210230283 | Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2021-07-29 |
20210230284 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES - The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures. | 2021-07-29 |
20210230285 | MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF - The present disclosure provides a multispecific antibody having increased in vivo sustainability, the multispecific antibody comprising one or more bioactive effector moieties linked to either or both of an N-terminal and a C-terminal of an antigen binding fragment Fab that binds to human serum albumin. | 2021-07-29 |
20210230286 | PEPTIDE HAVING HIGH AFFINITY FOR PD-L1 PROTEIN AND USE THEREOF - The present invention provides a peptide having high binding affinity for PD-L1 protein and use thereof. The peptide has an amino acid sequence of SEQ. ID. NO. 1, SEQ. ID. NO. 3 or SEQ. ID. NO. 4, or the peptide is a tandem or branched peptide with a single repeat or multiple repeats of SEQ. ID. NO. 1, SEQ. ID. NO. 3 and SEQ. ID. NO. 4 and has an amino acid sequence of SEQ. ID. NO. 5. The peptide can bind to human PD-L1 with high affinity, competitively block the affinity of PD-1/PD-L1 protein, block the negative regulatory tolerance pathway of human tumors, activate immunity and increase the lethality of T cells against tumor cells. | 2021-07-29 |
20210230287 | A MONOCLONAL ANTIBODY AGAINST HUMAN 4-1BB, METHOD FOR PREPARING THE SAME, AND USE THEREOF - Provided are novel fully human monoclonal antibodies that bind to human 4-1BB. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-4-1BB antibodies, vectors and host cells used for the expression of anti-4-1BB antibodies. The invention further provides methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of invention provide a very potent agent for the treatment of multiple cancers via modulating human immune function. | 2021-07-29 |
20210230288 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF - Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications. | 2021-07-29 |
20210230289 | SINGLE-CHAIN BISPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER - Methods and compositions are provided concerning a bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1, particularly in multiple myeloma patients. The bispecific CAR has advantages over dual or separate BCMA and CS1 CAR molecules. In some embodiments, there is a bispecific chimeric antigen receptor comprising a) a bispecific extracellular binding domain comprising both i) a BCMA-binding region and ii) a CSI-binding region; b) a single transmembrane domain; and, c) a single cytoplasmic region comprising a primary intracellular signaling domain. | 2021-07-29 |
20210230290 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele. | 2021-07-29 |
20210230291 | TARGETED ENGINEERED INTERFERON AND USES THEREOF - The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents. | 2021-07-29 |
20210230292 | ANTIBODY COMPLEX AND USES THEREOF - The present invention relates to a multivalent, preferably bivalent, antibody complex, more preferably a diabody, i.e. a bivalent scFv, capable of recognizing and binding the human protein CD99, a composition comprising said complex and the use thereof for diagnostic purposes and/or for the treatment and/or the follow-up of leukaemias and/or myelodysplastic syndromes. Furthermore, the present invention relates to antibodies, preferably monoclonal, of the immunoglobulins G group type capable of recognizing and binding the human protein CD99, a composition comprising said immunoglobulins and the medical use thereof, in particular for the treatment and/or the follow-up of cancer, preferably solid tumours that express CD99 and/or leukaemias and/or myelodysplastic syndromes. | 2021-07-29 |
20210230293 | ANTI-CD73 ANTIBODIES AND USES THEREOF - Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed. | 2021-07-29 |
20210230294 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY - Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed. | 2021-07-29 |
20210230295 | ANTIBODY BINDING TO AXL PROTEIN AND APPLICATION THEREOF - Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a K | 2021-07-29 |
20210230296 | ANTIBODIES - The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy. | 2021-07-29 |
20210230297 | Antibodies Useful for Detection of Human Carcinoma Antigen - This disclosure relates to diagnostic assays useful to detect a carcinoma from a sample and antibodies or binding fragments thereof useful in the diagnostic tests. In certain embodiments, this disclosure relates to antibodies or fragments that bind HCA, epiglycanin, and/or fragments thereof. In certain embodiments, this disclosure relates to anti-idiotypic antibodies or fragments that bind the variable regions of antibodies that bind HCA and/or epiglycanin. | 2021-07-29 |
20210230298 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF - Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 3rd, 5th and 9th amino acid residues of a light chain defined by Kabat method to charged amino acid residues. | 2021-07-29 |
20210230299 | MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIA - Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases. | 2021-07-29 |
20210230300 | INHIBITORS OF SHP2 - The present invention is related to an inhibitor or antagonist of SHP2 for the treatment and/or prevention of a neoplastic disease. | 2021-07-29 |
20210230301 | DIMERIC PROTEIN WITH TRIPLE MUTATIONS - The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution. | 2021-07-29 |
20210230302 | ANTI-CHI3L1 ANTIBODIES FOR THE DETECTION AND/OR TREATMENT OF NONALCOHOLIC FATTLY LIVER DISEASE/ NONALCOHOLIC STEATONHEPATITIS AND SUBSEQUENT COMPLICATIONS - The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma. | 2021-07-29 |
20210230303 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS - The present invention includes an antibody or antigen-binding fragment thereof that binds specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., influenza virus infections). | 2021-07-29 |
20210230304 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF - Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 17th, 18th and 20th amino acid residues of a light chain defined by Kabat method to charged amino acid residues. | 2021-07-29 |
20210230305 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF - Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 74th, 76th and 77th amino acid residues of a light chain defined by Kabat method to charged amino acid residues. | 2021-07-29 |
20210230306 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF - Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 5th, 9th and 22nd amino acid residues of a light chain defined by Kabat method to charged amino acid residues. | 2021-07-29 |
20210230307 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF - Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 77th, 79th and 81st amino acid residues of a light chain defined by Kabat method to charged amino acid residues. | 2021-07-29 |
20210230308 | CHIMERIC ANTIGEN RECEPTOR CELLS FOR TREATING SOLID TUMOR - The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin. | 2021-07-29 |
20210230309 | ANTI-LAMBDA MYELOMA ANTRIGEN (LMA) BINDING PROTEINS TO TREAT LMA-EXPRESSING CANCER AND AUTOIMMUNE DISORDERS - The present application is directed to anti-lambda myeloma antigen (LMA) binding proteins, wherein the binding protein is an antibody. Compositions comprising these antibodies and nucleic acids encoding these antibodies are also disclosed. These antibodies, compositions and nucleic acids may be used in the treatment of LMA expressing pathologies. | 2021-07-29 |
20210230310 | ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES - The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—
| 2021-07-29 |
20210230311 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT - Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers. | 2021-07-29 |
20210230312 | FIBROUS CELLULOSE AND METHOD FOR MANUFACTURING THE SAME, AND FIBROUS CELLULOSE COMPOSITE RESIN AND METHOD FOR MANUFACTURING THE SAME - A fibrous cellulose having a high resin reinforcing effect and a method for manufacturing the same, and a fibrous cellulose composite resin having high strength and a method for manufacturing the same. A fibrous cellulose has an average fiber width of 0.1 μm or more, an average fiber length of 0.02 to 3.0 mm, and a fibrillation ratio of 1.0% or more. A kneaded product of this fibrous cellulose and a resin is formed into a fibrous cellulose composite resin. In manufacturing the fibrous cellulose, a raw material fiber is defibrated so as to have an average fiber width of 0.1 μm or more, an average fiber length of 0.02 to 3.0 mm, and a fibrillation ratio of 1.0% or more. The fibrous cellulose obtained by this method and a resin are kneaded to manufacture a fibrous cellulose composite resin. | 2021-07-29 |
20210230313 | SULFUR-CONTAINING GLYCANS AND POLYSACCHARIDES AND METHODS OF CHEMOENZYMATIC SYNTHESIS THEREOF - Described herein are sulfur-containing glycosaminoglycans, and methods of making and using them. For example, heparosan and hyaluronan analogs are described which incorporate one or more sulfur-containing sugar units that include one or more free sulfhydryls and/or one or more thio-glycosidic linkages. In some embodiments, the glycosaminoglycans are included in pharmaceutical or bioadhesive compositions. | 2021-07-29 |
20210230314 | Method for Producing Ethylene-Vinyl Acetate Copolymer - A method of continuously producing an ethylene-vinyl acetate copolymer in a polymerization vessel containing a reaction liquid containing ethylene, vinyl acetate, a polymerization initiator and methanol, the polymerization vessel being connected via piping to a heat exchanger circulating a coolant, the method includes the steps of: supplying ethylene, the polymerization initiator and methanol to the polymerization vessel; introducing pressurized gas containing ethylene present in a gas phase portion of the polymerization vessel into the heat exchanger; supplying vinyl acetate cooled to between −50° C. and 23° C. to an upper portion of the heat exchanger; flowing vinyl acetate down in the heat exchanger while absorbing ethylene; letting vinyl acetate dissolving ethylene out of a bottom portion of the heat exchanger and adding to the reaction liquid in the polymerization vessel; and taking the reaction liquid out of the polymerization vessel. This provides a method of efficiently removing heat during polymerization of an ethylene-vinyl acetate copolymer. | 2021-07-29 |
20210230315 | POLYMER DISPERSIONS, THEIR PREPARATION AND USE - A multistage emulsion polymerization process comprises polymerizing a first monomer composition comprising from 50 to 95 weight percent of vinyl acetate, from 5 to 40 weight percent of at least one vinyl ester of a C | 2021-07-29 |
20210230316 | Preparation Method of Super Absorbent Polymer - The present disclosure relates to a preparation method of a super absorbent polymer capable of preparing a super absorbent polymer exhibiting an improved absorption rate while reducing an amount of a blowing agent used. The preparation method of a super absorbent polymer includes: preparing a monomer mixture including a water-soluble ethylene-based unsaturated monomer having at least partially neutralized acidic groups and an internal cross-linking agent; adjusting a dynamic pressure applied to the monomer mixture being transferred to 140 Pa or more by controlling a transfer rate while transferring the monomer mixture to a polymerization reactor; cross-linking and polymerizing the monomer mixture transferred to the polymerization reactor to form a hydrogel polymer; drying, pulverizing and classifying the hydrogel polymer to form a base resin powder; and further cross-linking a surface of the base resin powder in the presence of a surface cross-linking agent to form a surface cross-linked layer. | 2021-07-29 |
20210230317 | SPRAY-DRIED ZIEGLER-NATTA (PRO)CATALYST SYSTEMS - Methods of making spray-dried Ziegler-Natta (pro)catalyst systems containing titanium Ziegler-Natta (pro)catalysts, a hydrophobic silica carrier material, and tetrahydrofuran. The spray-dried Ziegler-Natta (pro)catalyst systems made by the method. Methods of polymerizing olefin (co)monomer(s) with the spray-dried Ziegler-Natta catalyst system to make polyolefin polymers, and the polyolefin polymers made thereby. | 2021-07-29 |
20210230318 | PROCESS FOR PREPARING CATALYSTS AND CATALYST COMPOSITIONS - Disclosed are support-activators and catalyst compositions comprising the support-activators for polymerizing olefins in which the support-activator includes clay heteroadduct, prepare from a colloidal phyllosilicate such as a colloidal smectite clay, which is chemically-modified with a heterocoagulation agent. By limiting the amount of heterocoagulation reagent relative to the colloidal smectite clay as described herein, the smectite heteroadduct support-activator is a porous and amorphous solid which can be readily isolated from the resulting slurry by a conventional filtration process, and which can activate metallocenes and related catalysts toward olefin polymerization. Related compositions and processes are disclosed. | 2021-07-29 |
20210230319 | PROCESS FOR PREPARING PROPYLENE POLYMERS - The present invention relates to a process for producing a propylene polymer, such as a propylene homopolymer, a propylene-ethylene random copolymer or a heterophasic propylene copolymer using a specific class of metallocene complexes in combination with a cocatalyst system comprising a boron containing cocatalyst and an aluminoxane cocatalyst, preferably in a multistage polymerization process including a gas phase polymerization step. | 2021-07-29 |
20210230320 | POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL, MOLDED PRODUCT, OPTICAL MATERIAL, AND PLASTIC LENS AND METHOD FOR MANUFACTURING SAME - A polymerizable composition for an optical material includes: an allyl carbonate compound (A) including two or more allyloxycarbonyl groups at a terminal which is represented by General Formula (1); and a radical polymerization initiator (B). The radical polymerization initiator (B) includes at least one kind of radical polymerization initiator (B1) which is a peroxyester-based radical polymerization initiator, and a radical polymerization initiator (B2). | 2021-07-29 |
20210230321 | HIGH MOLECULAR WEIGHT POLY(METHACRYLIC ACID) - The invention is generally related to a process for producing a relatively high molecular weight poly(methacrylic acid) (“PMAA”) in a water-based system. The process of the invention comprises polymerization of from about 1% to about 20% by weight of methacrylic acid in water or a water-based system in the presence of thiol compound and an azo radical initiator under controlled reaction and process conditions. A process of the invention can be easily scaled up into the pilot scale for producing large quantities of high molecular weight PMAAs. The invention is also related to high molecular weight poly(methacrylic acid)s obtained according to a process of the invention. | 2021-07-29 |
20210230322 | Polyethylene and Chlorinated Polyethylene Thereof - The polyethylene according to the present disclosure reacts with chlorine to prepare a chlorinated polyethylene having excellent processability during extrusion with a high tensile strength by implementing a molecular structure having a high content of medium molecular weight, and may also prepare a CPE compound including the chlorinated polyethylene. | 2021-07-29 |
20210230323 | Polyethylene and Chlorinated Polyethylene Thereof - The polyethylene according to the present disclosure has a short relaxation time and a uniform particle size, thereby preparing a chlorinated polyethylene excellent in chlorination productivity and glass transition temperature by reacting with chlorine. And, a PVC composition with improved impact strength may also be prepared by including the same. | 2021-07-29 |
20210230324 | Polyethylene and Chlorinated Polyethylene Thereof - The polyethylene according to the present invention has narrow particle size distribution, and can minimize a change in the crystal structure, and thus, it can be reacted with chlorine to prepare chlorinated polyethylene having excellent chlorination productivity and thermal stability. | 2021-07-29 |
20210230325 | ETHYLENE AND ISOPRENE COPOLYMER - A copolymer of ethylene and of isoprene, which comprises from 10 to 35 mol % of isoprene units, at least 70% of which are in the 3,4 configuration and a portion of which is in the 1,2 configuration is provided. A copolymer of this type with a reduced crystallinity is synthesized with a much higher productivity than its homologues of ethylene and of butadiene, and also confers improved curing properties on rubber compositions. | 2021-07-29 |
20210230326 | Olefin-Based Copolymer and Method for Preparing the Same - An olefin-based copolymer and method of making the same are disclosed herein. In some embodiments, the olefin-based copolymer includes a repeating unit derived from an alpha-olefin, wherein the alphas-olefin is present in the copolymer at 15 wt % to 45 wt %, wherein the copolymer has a density (d) of 0.85 to 0.89 g/cc, a melt index (MI), measured at 190° C. and 2.16 kg load, of 15 g/10 min to 100 g/10 min, and a hardness defined by Equation 1. The olefin-based copolymer has improved hardness and is highly flowable, and may show improved physical properties of tensile strength, elongation rate and flexural modulus. | 2021-07-29 |
20210230327 | FLUOROELASTOMER CURABLE COMPOSITION - The invention pertains to UV-curable compositions comprising a iodine-containing (per)fluoroelastomer, and well-defined amount of certain combinations of given photoinitiators and crosslinking which are particularly effective in delivering through low temperature UV curing crosslinked parts possessing outstanding mechanical properties. | 2021-07-29 |
20210230328 | Fluoropolymers with Very Low Amounts of a Fluorinated Alkanoic Acid or its Salts - Method of reducing the amount of a fluorinated acid or its salts from a fluoropolymer, the method comprises: (i) providing a composition containing particles of the fluoropolymer, (ii) contacting the fluoropolymer particles with a treatment composition comprising at least one organic liquid; and, optionally, further comprising (iii) isolating, washing and subjecting the fluoropolymer to drying treatment, and wherein the fluoropolymer contains units derived from tetrafluoroethene (TFE) and is selected from the group of fluoroelastomers and the group of fluoropolymers having a melting point of less than 150° C. Also provided are fluoropolymer and compositions containing such polymers that are essentially free of fluorinated acids and their salts. | 2021-07-29 |
20210230329 | METHODS FOR REDUCING OR PREVENTING COLLOIDS ADHESION AND/OR FOULING ON A SUBSTRATE, COMPOSITIONS, AND COPOLYMERS USEFUL THEREFOR - The present disclosure relates to the use of a composition for reducing or preventing colloids adhesion and/or fouling on a substrate, the composition comprising a copolymer having repeating units derived from one or more zwitterionic monomers and repeating units derived from one or more phosphorous acid monomers. | 2021-07-29 |
20210230330 | ACRYLONITRILE-BASED COPOLYMER FOR CARBON FIBER - Provided is an acrylonitrile-based copolymer for a carbon fiber which includes a sulfonate-based monomer unit, a carboxylic acid-based monomer unit, and an acrylonitrile-based monomer unit, and the acrylonitrile-based copolymer for a carbon fiber includes the sulfonate-based monomer unit at 0.55 to 1.55 mol %, and the carboxylic acid-based monomer unit at 0.60 to 1.40 mol %. | 2021-07-29 |
20210230331 | ASSOCIATIVE COPOLYMERS WITH HYDROPHOBIC QUATERNIZED (METH)ACRYLAMIDE AND (METH)ACRYLIC ACID DERIVATIVES - The present invention relates to a process for the preparation of a water-soluble copolymer comprising the step of reacting a monomer (a) of formula (I), (1) wherein Q | 2021-07-29 |
20210230332 | ALTERNATING COPOLYMER, METHOD OF PRODUCING ALTERNATING COPOLYMER, METHOD OF PRODUCING POLYMERIC COMPOUND, AND METHOD OF FORMING RESIST PATTERN - An alternating copolymer including a structural unit (a0-1) represented by general formula (a0-1) and a structural unit (a0-2) represented by general formula (a0-2) in which Rp | 2021-07-29 |
20210230333 | THERMOPLASTIC RESIN COMPOSITION - Provided is a thermoplastic resin composition which includes: a first graft copolymer including a C | 2021-07-29 |
20210230334 | METHOD OF PREPARING VINYL CYANIDE COMPOUND-CONJUGATED DIENE COMPOUND-AROMATIC VINYL COMPOUND GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION INCLUDING GRAFT COPOLYMER - A method of preparing a graft copolymer includes a step of performing coagulation by adding an acid coagulant to 100 parts by weight (based on solids) of graft copolymer latex prepared by graft-polymerizing an aromatic vinyl compound and a vinyl cyanide compound onto conjugated diene rubber latex; and a step of performing coagulation once more by adding a salt coagulant thereto. In a resulting graft copolymer, coagulation efficiency may be improved and the gloss of the prepared graft copolymer may be increased. In addition, since a b-value measured using a Hunter lab colorimeter and a b-value measured after being left at 250° C. for 15 minutes are low, the graft copolymer may have excellent color characteristics. In addition, since heating loss is low and scorch time is long, the graft copolymer may have excellent processing characteristics. | 2021-07-29 |
20210230335 | ALLYL-CONTAINING RESIN AND USES OF THE SAME - An allyl-containing resin is provided. The allyl-containing resin comprises a repeating unit comprising a structural unit represented by the following formula (I): | 2021-07-29 |
20210230336 | BLOCK COPOLYMER COMPOSITION INCLUDING IONIC GROUP, AND FILM - The present invention provides a block copolymer composition comprising a block copolymer B formed by introducing a functional group capable of forming a non-covalent bond into a block copolymer A including at least one aromatic vinyl polymer block and at least one conjugated diene polymer block, wherein: the block copolymer B includes an ionic group as the functional group capable of forming a non-covalent bond. | 2021-07-29 |
20210230337 | RESIN COMPOSITION FOR COVERING OPTICAL FIBER - The present disclosure relates to a resin composition for optical fiber coating, the resin composition including a base resin containing a urethane (meth)acrylate oligomer, a monomer, and a photopolymerization initiator; and inorganic oxide particles, in which a volume average particle size of the inorganic oxide particles as measured by a small angle X-ray scattering method is 800 nm or less, and a standardized dispersion of the volume average particle size is 60% or less. | 2021-07-29 |
20210230338 | BLOCK COPOLYMER AND METHOD OF PRODUCING SAME, HYDROGENATED BLOCK COPOLYMER, POLYMER COMPOSITION, AND SHAPED PRODUCT - Provided is a block copolymer that can serve as a precursor of a hydrogenated block copolymer. The block copolymer includes polymer blocks [A] and [B]. The polymer block [A] includes a polycyclic aromatic vinyl monomer unit including at least two monocycles selected from the group consisting of aromatic hydrocarbon monocycles and aromatic heteromonocycles. A mass ratio of proportional content of 1,2-vinyl bonds and proportional content of 1,4-vinyl bonds in the block copolymer is not less than 5/95 and not more than 90/10. | 2021-07-29 |
20210230339 | NOVEL HYDROPHOBIC PINNING MAT FOR DIRECTED SELF-ASSEMBLY OF DIBLOCK COPOLYMER NOVEL COMPOSITIONS AND PROCESSES FOR SELF-ASSEMBLY OF BLOCK COPOLYMERS - The present invention relates to a novel styrenic polymer comprised of the repeat units of structures (I), (II), and (III), wherein R | 2021-07-29 |
20210230340 | RESIN COMPOSITION FOR FORMING PHASE-SEPARATED STRUCTURE, METHOD FOR PRODUCING STRUCTURE INCLUDING PHASE-SEPARATED STRUCTURE, AND BLOCK COPOLYMER - A resin composition for forming a phase-separated structure includes a block copolymer having a block (b1) formed of a repeating structure of styrene units, the block (b1) being partially substituted with a constituent unit represented by the following General Formula (c1) and a block (b2) having a repeating structure of methyl methacrylate units. In the formula, R is a hydrogen atom or a methyl group and R | 2021-07-29 |
20210230341 | CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF - A curable resin composition for producing a three-dimensional object formed of a cured resin product comprises a polyfunctional urethane (meth)acrylate having a weight-average molecular weight of 1,000 or more and 60,000 or less; a monofunctional radically polymerizable compound having one radically polymerizable functional group in a molecule; a polyfunctional radically polymerizable compound other than the polyfunctional urethane (meth)acrylate; rubber particles; and a radical polymerization initiator. The monofunctional radically polymerizable compound includes a monofunctional acrylamide-based compound, and the content of the polyfunctional radically polymerizable compound other than polyfunctional urethane (meth)acrylate (particularly one having a radically polymerizable functional group equivalent of less than 300 g/eq) is controlled. | 2021-07-29 |
20210230342 | COMPOSITION CONTAINING MODIFIED BISPHENOL F - The invention relates to a composition that contains a binary mixture of bisphenol F and propoxylated bisphenol F. The aim of the invention is to provide aromatic polyols for preparing polyurethane-based and polyisocyanurate-based polymers, which ensure good handling from a technical point of view and good miscibility with the isocyanate component and render the end product flameproof. For this purpose, the invention devises a composition, which contains a binary mixture of ethoxylated bisphenol F and propoxylated bisphenol F in a weight ratio of 20:80 to 80:20. | 2021-07-29 |
20210230343 | URETHANE-CROSSLINKED BIODEGRADABLE ELASTOMERS - Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-) | 2021-07-29 |
20210230344 | THERMOPLASTIC POLYURETHANE COMPOSITION AND USE THEREOF - The present invention relates to a thermoplastic polyurethane composition and use thereof. The thermoplastic polyurethane composition comprises a polyurethane prepared from a polyester polyol and a polyisocyanate as well as an antioxidant. The thermoplastic polyurethane composition of the present invention can be used with other thermoplastic polymers in melt spinning process to prepare bicomponent fibers. | 2021-07-29 |
20210230345 | POLYURETHANE RESIN, PAINT, STRUCTURE, AND ARTICLE - Disclosed is a polyurethane resin containing a polyol component and an isocyanate component, wherein (1) the polyol component contains a polycarbonate diol component, and the isocyanate component contains a linear aliphatic isocyanate, (2) the polycarbonate diol component has a number-average molecular weight of 500 to 3000, and contains a diol-derived structure having 3 to 10 carbon atoms in the structure thereof, and (3) 10 mol % or more of the isocyanate component is a linear aliphatic isocyanate component having 4 to 10 carbon atoms. | 2021-07-29 |
20210230346 | SOUND ABSORBING URETHANE FOAM - According to one embodiment, a sound absorbing urethane foam is provided. In the sound absorbing urethane foam, a normal incidence sound absorbing coefficient at a time when a diameter is 29 mm and a thickness is 10 mm is 40% or more in an entire range of frequencies of 1000 Hz to 3150 Hz. | 2021-07-29 |
20210230347 | METHOD FOR PRODUCING A POLYURETHANE DISPERSION WITH A REDUCED FOAM FORMATION - The invention relates to a method for producing a polyurethane dispersion, having the steps of: I) providing isocyanate-functional prepolymers A) in a liquid phase comprising a solvent which can be mixed with water and which has a lower boiling point than water and II) adding NCO-reactive compounds to the isocyanate-functional prepolymers from step I) such that a reaction with the prepolymers is at least partly produced; wherein the liquid phase in step I) additionally comprises water and/or after step II), water is added to the mixture obtained in step II). A pressure p1 is applied to the liquid mixture with the isocyanate-functional prepolymers A) prior to and/or while carrying out step II), wherein p1 is less than the local atmospheric pressure present at said point in time. The pressure p1 is selected such that in step II), ≤50 mass. % (preferably >0 mass. % to ≤mass. %, more preferably ≥0.1 mass. % to ≤30 mass. % in particular ≥1 mass. % to ≤10 mass. %) of the originally provided solvent which can be mixed with water is distilled. | 2021-07-29 |
20210230348 | Polyurethane-Organopolysiloxanes Having Carbodiimide Groups - The invention relates to polyurethane and/or polyorganosiloxane copolymer compounds and salts thereof that contain carbodiimide moieties of formula [I]. Further, the invention relates to a process for the preparation thereof, to precursors for the preparation thereof, and to reactive compositions which contain such precursors and to their use for treating or finishing fibers, including hair and wool, and for permanently finishing, treating, impregnating textiles and leather or synthetic leather and other fibrous materials, and sheet materials and paper. | 2021-07-29 |
20210230349 | SKI BOOTS WITH TEMPERATURE-INDEPENDENT MODULUS OF ELASTICITY - The present invention relates to a thermoplastic polyurethane (TPU-1) obtained or obtainable by reaction of an isocyanate composition (IZ) comprising MDI with a polyol composition (PZ), wherein the polyol composition (PZ) comprises at least one polyol (P1) and a chain extender (KV1), wherein the polyol (P1) is selected from polytetrahydrofurans having an average molecular weight Mn in the range from 1200 to 2000 g/mol and the chain extender (KV1) is selected from the group consisting of 1,3-propanediol, 1,4-butanediol and 1,6-hexanediol and also to a process for producing a ski shoe or a part of a ski shoe from the thermoplastic polyurethane according to the invention and to the ski shoe or part of a ski shoe per se. | 2021-07-29 |
20210230350 | PREPARATION METHOD OF FLEXIBLE POLYURETHANE FOAM - A preparation method of a flexible polyurethane foam includes the following steps of: (1) subjecting an epoxidized vegetable oil, a benzoylformic acid, a basic catalyst, and an inert solvent to a ring-opening reaction in a first microchannel reactor of a microchannel reaction device to obtain a vegetable oil polyol; (2) subjecting the vegetable oil polyol obtained in the step (1), a propylene oxide and an inert solvent to an addition polymerization reaction in a second microchannel reactor of the microchannel reaction device to obtain a vegetable oil polyol for flexible polyurethane foam; and (3) using the vegetable oil polyol for flexible polyurethane foam obtained in the step (2) as the unique polyol, and subjecting the same and an isocyanate polyol to a foaming reaction to obtain the flexible polyurethane foam. | 2021-07-29 |